Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
961 to 980 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Motor unit recovery following Smn restoration in mouse models of spinal muscular atrophy. | Hum Mol Genet | 2022 | 35551393 | PubTator, text mining | PubMed |
| Scoliosis Orthopedic Surgery Combined With Nusinersen Intrathecal Injection Significantly Improved the Outcome of Spinal Muscular Atrophy Patient: A Case Report. | Front Neurol | 2022 | 35547367 | PubTator, text mining | PubMed |
| NOVA1 promotes SMN2 exon 7 splicing by binding the UCAC motif and increases SMN protein expression. | Neural Regen Res | 2022 | 35535907 | PubTator, text mining | PubMed |
| The Progress and Promise of RNA Medicine─An Arsenal of Targeted Treatments. | J Med Chem | 2022 | 35533054 | PubTator, text mining | PubMed |
| Re-analysis of the Hungarian amyotrophic lateral sclerosis population and evaluation of novel ALS genetic risk variants. | Neurobiol Aging | 2022 | 35525134 | PubTator, text mining | PubMed |
| Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening. | Eur J Pediatr | 2022 | 35522315 | PubTator, text mining | PubMed |
| Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study. | PLoS One | 2022 | 35511762 | PubTator, text mining | PubMed |
| Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients. | Eur J Neurol | 2022 | 35510740 | PubTator, text mining | PubMed |
| A Window of Opportunity for Newborn Screening. | Mol Diagn Ther | 2022 | 35507129 | PubTator, text mining | PubMed |
| Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases. | RNA Biol | 2022 | 35482908 | PubTator, text mining | PubMed |
| Single Stranded Fully Modified-Phosphorothioate Oligonucleotides can Induce Structured Nuclear Inclusions, Alter Nuclear Protein Localization and Disturb the Transcriptome In Vitro. | Front Genet | 2022 | 35464859 | PubTator, text mining | PubMed |
| Genome Integrity and Neurological Disease. | Int J Mol Sci | 2022 | 35456958 | PubTator, text mining | PubMed |
| High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed SMN2 Splicing in Patient Fibroblasts. | Genes (Basel) | 2022 | 35456491 | PubTator, text mining | PubMed |
| SRSF6 Regulates the Alternative Splicing of the Apoptotic Fas Gene by Targeting a Novel RNA Sequence. | Cancers (Basel) | 2022 | 35454897 | PubTator, text mining | PubMed |
| RNA therapy: rich history, various applications and unlimited future prospects. | Exp Mol Med | 2022 | 35440755 | PubTator, text mining | PubMed |
| SMN-deficient cells exhibit increased ribosomal DNA damage. | Life Sci Alliance | 2022 | 35440492 | PubTator, text mining | PubMed |
| Rescue of mis-splicing of a common SLC26A4 mutant associated with sensorineural hearing loss by antisense oligonucleotides. | Mol Ther Nucleic Acids | 2022 | 35433113 | PubTator, text mining | PubMed |
| Spinal Muscular Atrophy - Is Newborn Screening Too Late for Children with Two SMN2 Copies? | J Neuromuscul Dis | 2022 | 35431259 | PubTator, text mining | PubMed |
| Unravelling the neuroprotective mechanisms of carotenes in differentiated human neural cells: Biochemical and proteomic approaches. | Food Chem (Oxf) | 2022 | 35415676 | PubTator, text mining | PubMed |
| Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of SMN2 in SMA Type I Fibroblasts. | Int J Mol Sci | 2022 | 35409296 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=49